The medicines business | A question to investigate
Before a product leaves the portfolio
A product can be commercially difficult to sustain and still matter to the people and services relying on it. The portfolio decision therefore needs more than a margin column. It needs an account of supply implications, alternatives, timing and the work required to make a responsible transition. NEUVIOR is interested in helping medicines businesses examine that decision clearly, without assuming that continued supply is always feasible or that withdrawal is a purely commercial event.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Make the competing realities visible
A low-volume presentation may carry manufacturing complexity, packaging constraints or a fragile supplier dependency. Continuing it may require investment; discontinuing it may create a different burden. A decision paper should separate these realities rather than make one disappear. The aim is to compare credible options with their conditions: sustain, redesign, transfer where feasible, change supply arrangements or discontinue through the applicable process. Some options may prove unavailable once their requirements are examined.
Authorisation and supply reporting are distinct
MHRA provides a process for cancelling a marketing authorisation (MHRA, n.d.). DHSC provides reporting guidance for shortages and discontinuations (DHSC, 2019). These are different parts of the context, with responsibilities that cannot be inferred from a financial model. A proposed review would identify the relevant regulatory and supply owners early. It would not interpret an exploratory portfolio scenario as authority to withdraw a product or imply that one administrative step resolves all reporting and transition questions.
Compare options over the same horizon
An apparent loss can depend on allocation of shared manufacturing costs; an apparent solution can depend on a future volume increase that has not been evidenced. The comparison should show contribution assumptions, required capital, capacity implications and the operational sequence. It should also identify which alternatives depend on another party’s willingness or on regulatory approval. Those dependencies must remain conditional rather than becoming assured benefits in a preferred-option narrative.
A decision record that preserves the alternatives
A useful deliverable would show the conditions under which each portfolio option remains feasible, alongside the work and approvals still required. It would preserve why an alternative was rejected and which new evidence could change that judgement. The board would receive a traceable decision record rather than a retrospective justification for a preferred commercial answer.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A medicines or implementation team considering an AI-supported evidence review.
Would a quicker review make the decision better?
The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.
A proposition to investigate
Less preparation. The same ability to challenge.
An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.
The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether one defined review task merits an agreed evaluation.
- The comparator
- The team's existing complete review process, including checking and corrections.
- The evidence
- Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
- Stop or redesign
- Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefA proposed PHARMORIS evaluation
We would begin with one historical or currently unresolved portfolio question, using approved aggregate commercial and operational information. Inputs could include cost ranges, supply history, manufacturing dependencies and a responsibility map for the relevant processes. The comparator would be the existing portfolio paper. A proposed evidence-linked brief would be reviewed for completeness and consistency, without changing supply, contacting customers or making regulatory decisions. Any commercially sensitive material would remain within agreed access boundaries.
What useful decision evidence looks like
Candidate measures include material assumptions challenged before sign-off, alternatives rejected for explicit reasons, dependencies assigned to owners and the reproducibility of the financial comparison. Scenario analysis should show which assumptions change the preferred option. The evaluation cannot establish that a discontinuation is safe, socially optimal or commercially successful. Those conclusions need broader evidence and the authority of the organisations and professionals responsible for supply and patient care.
Where the work should stop
We would pause if supply implications cannot be described adequately or if the decision is being presented as reversible when it is not. The evaluation should stop if confidential competitor information is required inappropriately or if the desired conclusion is fixed before the options are reviewed. A legitimate result may be that a short-term commercial decision needs further regulatory or supply analysis. Another may be that no feasible alternative changes the underlying portfolio constraint.
A conversation before a difficult commitment
A portfolio, supply or finance leader can bring one product question and the alternatives currently under consideration. Explain the decision deadline, what is known and which consequence remains uncertain. We can explore a bounded review that brings those assumptions into one inspectable discussion. The incentive is a more defensible commitment, with the organisation understanding the commercial case, the limits of the evidence and the work that must accompany whichever option it chooses.
Sources and scope
MHRA | Cancelling a marketing authorisation | DHSC | Shortage and discontinuation reporting
MHRA (n.d.) Cancelling a marketing authorisation. Available at: https://www.gov.uk/guidance/cancel-a-medicines-marketing-authorisation-or-other-licence (Accessed: 14 October 2026).
DHSC (2019) Shortage and discontinuation reporting. Available at: https://www.gov.uk/government/publications/reporting-requirements-for-medicine-shortages-and-discontinuations (Accessed: 14 October 2026).
Another useful angle.
- Before a shortage becomes everybody’s problem
A proposed readiness review for marketing authorisation holders connecting supply evidence, reporting ownership and action.
- A forecast needs a reason to be believed
Explore demand uncertainty, stock movement and the evidence needed before a pharmaceutical supply decision changes.
- From a changed document to a clear next question
A proposed regulatory-intelligence triage review connecting official changes, product relevance and accountable assessment.